MA1-40244

antibody from Invitrogen Antibodies

Targeting: ASGR1 CLEC4H1

Western blot (Recommended by provider)

ELISA (Recommended by provider)

Immunohistochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA1-40244

Provider

Invitrogen Antibodies

Product name

ASGR1 Monoclonal Antibody (8D7)

Antibody type

Monoclonal

Antigen

Other

Description

Applications Reported: This L243 antibody has been reported for use in flow cytometric analysis.

Reactivity

Human, Rat

Host

Mouse

Isotype

IgG

Antibody clone number

8D7

Vial size

100 µg

Concentration

0.1 mg/mL

Storage

4° C

References

Submitted references

Generation of qualified clinical-grade functional hepatocytes from human embryonic stem cells in chemically defined conditions.

Li Z, Wu J, Wang L, Han W, Yu J, Liu X, Wang Y, Zhang Y, Feng G, Li W, Stacey GN, Gu Q, Hu B, Wang L, Zhou Q, Hao J
Cell death & disease 2019 Oct 10;10(10):763

---

Maturation of induced pluripotent stem cell derived hepatocytes by 3D-culture.

Gieseck RL 3rd, Hannan NR, Bort R, Hanley NA, Drake RA, Cameron GW, Wynn TA, Vallier L
PloS one 2014;9(1):e86372

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 2 Functional comparison of IPSC-Hep 3D clump culture versus traditional 2D culture. ( A ) Oil red O and periodic acid staining demonstrating lipid storage and glycogen synthesis in both 2D and 3D clump cultures. ( B ) qPCR analysis of select phase I and phase II enzymes, hepatic transporters, and other hepatic markers demonstrating a shift towards a more mature phenotype in the 3D clump cultures (fold expression to undifferentiated IPSCs; mean +- s.d.; n = 3 biological replicates). ( C ) Confocal micrographs comparing the presence and localization of hepatic markers within the two culture systems (scale bar = 100 microns). ( D ) CYP3A4 activity of the two culture conditions measured over a period of 75 days (mean +- s.d.; n = 3 biological replicates).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 4 Differentiation of hESCs into HLCs. a The relative hepatocyte ( ALB , AAT , CK18 , and ASGPR1 ), cholangiocyte ( SOX9 ), and hepatoblast ( AFP ) gene expression levels of day 19 differentiated cells with different treatments (groups A and B) were determined by qPCR. HGF (hepatocyte growth factor, 20 ng/mL); OSM (oncostatin M, 20 ng/mL); Dex (dexamethasone, 10 uM); SB431542 (TGFbeta inhibitor, 2 uM); and RO4929097 (Notch inhibitor, 1 uM). b Immunofluorescence analysis of ALB, AAT, ASGPR1, and CK18 expression in group B-induced differentiated cells on day 19. c The expression levels of ALB and ASGPR1 in group B-induced differentiated cells were determined by flow cytometry on day 19. Isotype control antibodies were used as controls. d The relative hepatocyte ( ALB , AAT , CK18 , ASGPR1 , and AFP ) gene expression levels of differentiated HLCs (group B) compared with those of hESCs and primary human hepatocytes (PHHs) were determined by qPCR. e Albumin secretion of HLCs (black line) on days 12, 14, 16, 18, and 20 and PHHs (dotted line) on day 2 were determined by ELISA. * p < 0.05, ** p < 0.01; data are represented as the mean +- SD. Scale bar, 50 um.